Natera, Inc.
NTRA
Schneider v. Natera, Inc. et al., (Case No. 1:22-cv-00398), W.D. Tex.
On March 9, 2022, before the market opened, Hindenburg Research issued a short report alleging that “Natera’s revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers.” The report includes other potential issues at the prenatal testing company.
Shares of Natera, Inc. stock dropped more than 15% in premarket trading on March 9, 2022.
Then on March 15, 2022, before the market opened, CareDX, Inc. announced that it won its false advertising case against Natera. On this news shares of Natera, Inc. stock fell 12% in premarket trading on March 15, 2022.
Lead Plaintiff deadline
June 27, 2022
class period
February 26, 2020
to
April 19, 2022
Case Documents
No documents available. Contact us if you need a case document.
